Hybrigenics receives first patent grant on chemical inhibitors of Ubiquitin-Specific Proteases
Proteases play a key role in a number of pathological processes and several protease inhibitors are already available as drugs (for example, ACE-inhibitors for hypertension and HIV-1 proteases inhibitors in AIDS). Ubiquitin-Specific Proteases are proteases responsible for the recycling of proteins. Inhibiting the recycling of oncoproteins (proteins involved in the development of cancer) will force their degradation and it is expected that this will slow-down the progression of certain cancers.
The granting of this patent extends the intellectual property portfolio of Hybrigenics: it is its first patent in the field of innovative small molecules with drug potential. This new patent further indicates Hybrigenics' progress towards pharmaceutical and therapeutic applications, moving downstream of the drug discovery pipeline after having focused on target research.
The recently granted European patent EP1749822 will subsequently be registered in 32 European countries. The corresponding worldwide application under the "Patent Cooperation Treaty" (PCT) is under way to extend further its geographical coverage, in particular to include the USA. Hybrigenics expects a rapid growth of its patenting activity around USPs and their inhibitors to strengthen its pioneer position in the field.
"This patent clearly positions Hybrigenics as a company with its own intellectual property in the field of a new class of potential innovative pharmaceutical ingredients," said Rémi Delansorne, CEO at Hybrigenics.
Other news from the department research and development
Most read news
More news from our other portals
See the theme worlds for related content
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.
Topic world biopharmaceutical manufacturing
Biopharmaceutical production plays a crucial role in the development and manufacture of biologics, which are essential for the treatment of various serious diseases. Various key technologies and processes of the modern biopharmaceutical industry are used, such as cell cultures, fermentation processes and the purification of biological substances, which are necessary for the production of vaccines, monoclonal antibodies and other biological drugs.